There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare penny stocks to buy according to hedge funds. On March 30, ...

Cautionary Language Concerning Forward-Looking Statements ...

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

C-mo Medical Solutions receives CE Mark for its novel AI-powered cough monitoring in patients: Lisbon, Portugal Saturday, April 18, 2026, 10:00 Hrs [IST] C-mo Medical Solutions, a ...

Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

Regulatory milestone supports broader adoption of C-mo's privacy-preserving technology in clinical research and medical practiceApproval covers the biosensor, automated cough monitoring algorithms and ...